[High-dose inhaled beclomethasone dipropionate and maximal improvements in patients with stable chronic obstructive pulmonary disease].

Abstract

High doses of inhaled beclomethasone dipropionate (BDP) are effective in some patients with chronic obstructive pulmonary disease (COPD). However, dose-response data for this agent are limited. To determine whether patients receive maximum benefit from 1600 micrograms of BDP, we performed a randomized, double-blind, placebo-controlled, cross-over trial. Twenty-one patients with stable COPD [mean +/- SD: age, 69.1 +/- 6.8 yrs; FEV1, 0.86 +/- 0.28 L] were treated with both inhaled bronchodilators and 1600 micrograms of BDP daily for at least 3 months. Each patient received 30 mg of oral prednisolone or a placebo for 3 weeks. In addition to end-point spirometric assessments daily peak expiratory flow rate, symptom scores, and scores on a chronic respiratory disease questionnaire were recorded for the last week of each 3-week period. Oral prednisolone did not improve FEV1, FVC, symptoms or scores on the questionnaire. We conclude that 1600 micrograms of BDP in addition to inhaled bronchodilators produces maximal improvements in stable patients with COPD.

• Authors: M Zhang, K Nishimura, A Ikeda, M Tsukino, H Koyama, T Izumi
• Journal: Nihon Kyobu Shikkan Gakkai zasshi (Nihon Kyobu Shikkan Gakkai Zasshi) Vol. 33 Issue 12 Pg. 1386-1391 (Dec 1995) ISSN: 0301-1542 [Print] Japan
• PMID: 8821992 (Publication Type: Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Anti-Inflammatory Agents
• Bronchodilator Agents
• Beclomethasone

Topics

• Administration, Inhalation
• Aged
• Anti-Inflammatory Agents (administration & dosage)
• Beclomethasone (administration & dosage)
• Bronchodilator Agents (administration & dosage)
• Cross-Over Studies
• Double-Blind Method
• Female
• Humans
• Lung Diseases, Obstructive (drug therapy)
• Male